Figures computed from official regulatory filings — .
Analysttarget 23.73 USD (+219%) · consensus 4.36/5 · 9 buy · 2 hold · 0 sell
Ownershipinsiders 6.55% · institutions 65.23% · short 12.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for REGENXBIO Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys437 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Malzahn Craig | Other | $2.2K | SEC |
| Chan Mitchell | Other | $45.7K | SEC |
| Ciongoli Gregory Austin | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ciongoli Gregory Austin | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ciongoli Gregory Austin | Buy | $499.7K | conv 54 | SEC |
| Ciongoli Gregory Austin | Buy | $449.7K | conv 65First in 12mo | SEC |
| PAKOLA STEVE | Other | $72.4K | SEC |
| Christmas Patrick J. | Other | $45.5K | SEC |
| Simpson Curran | Award | $14.8K | Unusual size | SEC |
| Simpson Curran | Award | $6.7K | SEC |
| Simpson Curran | Other | $89.2K | SEC |
| PAKOLA STEVE | Sell | $29.5K | SEC |
| PAKOLA STEVE | Exercise | $17K | SEC |
| PAKOLA STEVE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PAKOLA STEVE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PAKOLA STEVE | Sell | $216.5K | SEC |
| PAKOLA STEVE | Exercise | $288.7K | SEC |
| PAKOLA STEVE | Sell | $472.3K | Unusual size | SEC |
| Fox Allan M. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tasse Daniel | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MIGAUSKY GEORGE Vtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mills Kenneth T. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bennett Jean | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zachary Jennifer | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fox Allan M. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |